Kura Oncology Stock Analysis

Kura Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The book value of Kura Oncology was now reported as 5.45. The company recorded a loss per share of 2.35. Kura Oncology had not issued any dividends in recent years. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people. To find out more about Kura Oncology contact Troy JD at 858 500 8800 or learn more at https://kuraoncology.com.

Kura Oncology Investment Alerts

Kura Oncology Upcoming and Recent Events

Kura Largest EPS Surprises

View All Earnings Estimates

Kura Oncology Environmental, Social, and Governance (ESG) Scores

Kura Stock Institutional Investors

Note, although Kura Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kura Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.24 B.

Kura Profitablity

Management Efficiency

Kura Oncology has return on total asset (ROA) of (0.2854) % which means that it has lost $0.2854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4628) %, meaning that it created substantial loss on money invested by shareholders. Kura Oncology's management efficiency ratios could be used to measure how well Kura Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 21, 2024, Return On Tangible Assets is expected to decline to -0.36. The current year's Return On Capital Employed is expected to grow to -0.38. At present, Kura Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 454.1 M, whereas Return On Tangible Assets are forecasted to decline to (0.36).

Technical Drivers

As of the 21st of November, Kura Oncology secures the Standard Deviation of 2.33, risk adjusted performance of (0.1), and Mean Deviation of 1.7. Kura Oncology technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.

Kura Oncology Price Movement Analysis

Kura Oncology Insider Trading Activities

Kura Oncology Outstanding Bonds

Kura Oncology Predictive Daily Indicators

Kura Oncology Corporate Filings

Kura Oncology Forecast Models

Kura Oncology's time-series forecasting models are one of many Kura Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kura Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kura Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kura shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kura Oncology. By using and applying Kura Stock analysis, traders can create a robust methodology for identifying Kura entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kura analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kura analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Kura Oncology stock analysis indicators help investors evaluate how Kura Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kura Oncology shares will generate the highest return on investment. By understating and applying Kura Oncology stock analysis, traders can identify Kura Oncology position entry and exit signals to maximize returns.

When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.